Compugen to Present Research at the Single Cell Genomics 2025 Conference
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, will present research at the Single Cell Genomics 2025 Conference in Stockholm, Sweden from September 15-17, 2025. The presentation will showcase the company's AI/ML-powered computational capabilities in analyzing spatial context of cancer biology.
Dr. Roy Granit, Senior Director and Head of Computational Discovery, will present research titled "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer" on September 15, 2025, at 2:10 PM CET. The poster presentation (ID: P035) will be available on Compugen's website after the conference.
Compugen (NASDAQ: CGEN), azienda in fase clinica specializzata in immunoterapia oncologica, presenter脿 i suoi studi al Single Cell Genomics 2025 Conference a Stoccolma, Svezia, dal 15 al 17 settembre 2025. La presentazione metter脿 in luce le capacit脿 computazionali basate su AI/ML dell'azienda nell'analisi del contesto spaziale della biologia tumorale.
Il Dr. Roy Granit, Senior Director e Head of Computational Discovery, presenter脿 lo studio intitolato "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer" il 15 settembre 2025 alle 14:10 CET. Il poster (ID: P035) sar脿 disponibile sul sito web di Compugen dopo la conclusione della conferenza.
Compugen (NASDAQ: CGEN), una compa帽铆a en fase cl铆nica dedicada a la inmunoterapia contra el c谩ncer, presentar谩 investigaciones en la Single Cell Genomics 2025 Conference en Estocolmo, Suecia, del 15 al 17 de septiembre de 2025. La presentaci贸n mostrar谩 las capacidades computacionales impulsadas por IA/ML de la empresa para analizar el contexto espacial de la biolog铆a del c谩ncer.
El Dr. Roy Granit, Director Senior y Jefe de Computational Discovery, expondr谩 la investigaci贸n titulada "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer" el 15 de septiembre de 2025 a las 14:10 CET. La presentaci贸n en p贸ster (ID: P035) estar谩 disponible en el sitio web de Compugen tras la conferencia.
Compugen (NASDAQ: CGEN), 鞛勳儊 雼硠鞚� 鞎� 氅挫棴旃橂 旮办梾,鞚� 2025雲� 9鞗� 15鞚茧秬韯� 17鞚缄箤歆� 鞀れ洦雿� 鞀ろ啞頇�毽勳棎靹� 鞐措Μ電� Single Cell Genomics 2025 Conference鞐愳劀 鞐瓣惮毳� 氚滍憸頃╇媹雼�. 鞚措矆 氚滍憸鞐愳劀電� 鞎� 靸濍頃欖潣 瓿店皠鞝� 毵ル澖鞚� 攵勳劃頃橁赴 鞙勴暅 鞛愳偓鞚� AI/ML 旮半皹 瓿勳偘 鞐焿鞚� 靹犽炒鞚� 鞓堨爼鞛呺媹雼�.
Roy Granit 氚曥偓(靾橃劃 鞚挫偓 瓴� Computational Discovery 毂呾瀯鞛�)電� "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer"霛茧姅 鞝滊鞚� 鞐瓣惮毳� 2025雲� 9鞗� 15鞚� CET 旮办 鞓ろ泟 2鞁� 10攵�鞐� 氚滍憸頃╇媹雼�. 韽姢韯� 氚滍憸(ID: P035)電� 頃欗殞 膦呺 頉� Compugen 鞗轨偓鞚错姼鞐愳劀 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Compugen (NASDAQ: CGEN), soci茅t茅 en phase clinique sp茅cialis茅e en immunoth茅rapie anticanc茅reuse, pr茅sentera des travaux lors de la Single Cell Genomics 2025 Conference 脿 Stockholm, Su猫de, du 15 au 17 septembre 2025. La pr茅sentation mettra en avant les capacit茅s computationnelles aliment茅es par l'IA/ML de l'entreprise pour analyser le contexte spatial de la biologie du cancer.
Le Dr Roy Granit, Senior Director et Head of Computational Discovery, pr茅sentera l'茅tude intitul茅e "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer" le 15 septembre 2025 脿 14h10 CET. La pr茅sentation sous forme de poster (ID : P035) sera disponible sur le site web de Compugen apr猫s la conf茅rence.
Compugen (NASDAQ: CGEN), ein biopharmazeutisches Unternehmen in klinischer Phase f眉r Krebsimmuntherapien, wird Forschungsergebnisse auf der Single Cell Genomics 2025 Conference in Stockholm, Schweden, vom 15. bis 17. September 2025 vorstellen. Die Pr盲sentation zeigt die AI/ML-gest眉tzten Rechenf盲higkeiten des Unternehmens zur Analyse des r盲umlichen Kontexts der Krebsbiologie.
Dr. Roy Granit, Senior Director und Leiter von Computational Discovery, wird die Forschung mit dem Titel "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer" am 15. September 2025 um 14:10 Uhr CET vorstellen. Die Posterpr盲sentation (ID: P035) wird nach der Konferenz auf der Website von Compugen verf眉gbar sein.
- None.
- None.
HOLON,
This research reflects Compugen's computational capabilities in understanding the spatial context of complex cancer biology that may inform drug discovery efforts and therapeutic strategies to potentially provide benefit to cancer patients.听
Poster and short talk details:
Title:听Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer
Presenting author: Roy Granit, Ph.D., Senior Director, Head of Computational Discovery, Compugen
Poster ID: P035
Date of presentation: September 15, 2025, at 2:10 PM CET
Poster will be available in the publications section of Compugen's website, , following presentation.
础产辞耻迟听颁辞尘辫耻驳别苍
Compugen听is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen鈩�) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902,听a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.听GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage听immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen听is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
贰尘补颈濒:听[email protected]
Tel: +1听(628)听241-0071听
听
View original content:
SOURCE Compugen Ltd.
FAQ
When is Compugen (CGEN) presenting at the Single Cell Genomics 2025 Conference?
What research will Compugen present at the Single Cell Genomics Conference?
Who will be presenting Compugen's research at the Single Cell Genomics Conference?
Where can investors access Compugen's Single Cell Genomics Conference presentation?
